Gastroesophageal Reflux Disease (GERD) Therapeutics Market Opportunities and Forecast 2014 - 2025
The global Gastroesophageal Reflux Disease (GERD) therapeutics market is expected to reach USD 4.34 billion by 2025, according to a new study by Radiant insights, inc. The incidence of acid reflux disorder, also known as heartburn, is rapidly increasing worldwide. Various studies state that almost every person experiences acid reflux once in a lifetime. The overall market has been experiencing a downturn in terms of revenue in the past several years as the leading drugs for GERD treatment have lost their patent protection, with their market shares now largely consumed by over-the-counter (OTC) and generic medications. Although loss of exclusivity of high-grossing drugs have caused a market fall-off, the demand for acid reducing drugs due to the high prevalence and incidence levels of GERD will prove beneficial to the industry from a commercial standpoint. GERD is one of the commonly observed recurrent gastrointestinal disorders worldwide. The prevalence of acid reflux and related